212: Applause-worthy cancer data, the long wait for Novavax, & the next FDA controversy
The Readout Loud
00:00
Do You Know if the Placebo Arm Is Better Than Expected?
Praxis, a smallish company that went public a couple of years ago, was developing this depression drug. Company didn't release details other than saying the drug failed on its primary and secondary end points. Until fairly recently, there had not been a new, approved mechanism to treat depression in a number of decades.
Transcript
Play full episode
